IBI-363

Cat. No.: HY-P991740 Purity: 99.60%: Data Sheet
COA

SDS

FAQs
Technical Support

IBI-363 is a PD-1/IL-2 bispecific antibody with functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Rα but attenuates binding ability to IL-2Rβ and IL-2Rγ to reduce toxicity. The PD-1 binding arm of IBI-363 enables PD-1 blockade and selective delivery of IL-2. IBI-363 can be used in cancer research, such as non-small cell lung cancer.

For research use only. We do not sell to patients.

Size		Stock
1 mg		Check price and availability

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Biological Activity
Purity & Documentation
References
Customer Review

Description

Species Reactivity

Human

IC₅₀ & Target^[1]

IL-2

In Vitro

IBI363 is a PD-1/IL-2α-biased bispecific antibody fusion protein designed to block the PD-1 immune checkpoint and reinvigorate exhausted tumor-specific T cells via cis-activation of α-biased IL-2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Gene ID

5133 [NCBI]

Accession

Q15116

Target

PD-1 & IL-2α

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

112.48 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[IBI-363]

Shipping

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

PD-1/IL-2 α-bias bispecific antibody

Purity & Documentation

Purity: 99.60%

Select Batch:

Data Sheet (256 KB) SDS (251 KB)

COA (232 KB) SDS-PAGE (496 KB) SEC-HPLC (525 KB)

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Zhou J, et al. MA11. 04 first-in-class PD-1/IL-2 bispecific antibody IBI363 in patients with advanced non-small cell lung cancer in a phase I study[J]. Journal of Thoracic Oncology, 2024, 19(10): S97.

IBI-363 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IBI-363IBI363IBI 363PD-1/PD-L1Interleukin RelatedPD-1/Programmed death-ligand 1ILIL-2 signalingadvanced non-small cell lung cancerexhausted tumor-specific T cellsPD-1IL-2 receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *